Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 1Gastrointestinal 1

Conditions

Severe combined immunodeficiency with sensitivity to ionizing radiation 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 10Cyclophosphamide 10Docetaxel 8atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Gemcitabine 5Filgrastim 5durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × amatuximab × Other solid neoplasm × Clear all
NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡